Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > April 3, 2023
Daily News
April 3, 2023
- Sanofi Seeks Dupixent Label Expansion into CSU in Japan
April 3, 2023
- Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
- Novartis Takes Over Radioligand Therapy Lutathera from Fujifilm in Japan
April 3, 2023
- Shionogi’s Xocova Now Available through Normal Commercial Channel
April 3, 2023
- Entyvio Hits Primary Goal in Pouchitis Study: Takeda
April 3, 2023
- 32 Hypertension Meds under PMDA Safety Review for Women of Childbearing Potential
April 3, 2023
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…